Hydroxyethylamine derivatives for the treatment of alzheimer's disease
申请人:Demont H Emmanuel
公开号:US20060025459A1
公开(公告)日:2006-02-02
The present invention relates to novel hydroxyethylamine compounds having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.
HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
申请人:GLAXO GROUP LIMITED
公开号:EP1567488B1
公开(公告)日:2007-02-21
US7253198B2
申请人:——
公开号:US7253198B2
公开(公告)日:2007-08-07
Direct Access to Primary Amines from Alkenes by Selective Metal‐Free Hydroamination
作者:Yi‐Dan Du、Bi‐Hong Chen、Wei Shu
DOI:10.1002/anie.202016679
日期:2021.4.26
selective synthesis of primary aminesfrom easily available precursors is attractive yet challenging. Herein, we report the rapid synthesis of primary aminesfrom alkenes via metal‐free regioselective hydroamination at room temperature. Ammonium carbonate was used as ammonia surrogate for the first time, allowing for efficient conversion of terminal and internal alkenes into linear, α‐branched, and α‐tertiary